Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 19:16:34 GMT 2025
by
admin
on
Tue Apr 01 19:16:34 GMT 2025
|
| Protein Type | RECEPTOR |
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
P6W5IXV8V9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
P6W5IXV8V9
Created by
admin on Tue Apr 01 19:16:34 GMT 2025 , Edited by admin on Tue Apr 01 19:16:34 GMT 2025
|
PRIMARY | |||
|
P42262
Created by
admin on Tue Apr 01 19:16:34 GMT 2025 , Edited by admin on Tue Apr 01 19:16:34 GMT 2025
|
PRIMARY | |||
|
P42262
Created by
admin on Tue Apr 01 19:16:34 GMT 2025 , Edited by admin on Tue Apr 01 19:16:34 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_54 | 1_306 |
| 4_54 | 4_306 |
| 2_54 | 2_306 |
| 3_54 | 3_306 |
| 1_715 | 1_770 |
| 4_715 | 4_770 |
| 2_715 | 2_770 |
| 3_715 | 3_770 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_232 |
| N | 1_346 |
| N | 1_382 |
| N | 1_389 |
| N | 2_232 |
| N | 2_346 |
| N | 2_382 |
| N | 2_389 |
| N | 3_232 |
| N | 3_346 |
| N | 3_382 |
| N | 3_389 |
| N | 4_232 |
| N | 4_346 |
| N | 4_382 |
| N | 4_389 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
AGONIST -> TARGET |
The endogenous agonist
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
NEGATIVE ALLOSTERIC MODULATOR (NAM)->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
RADIOLIGAND->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
NEGATIVE ALLOSTERIC MODULATOR (NAM)->TARGET |
|
||
|
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
High-impact AMPAR PAM decreases both deactivation and desensitization together to enhance and prolong synaptic currents.
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents
|
||
|
NEGATIVE ALLOSTERIC MODULATOR (NAM)->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
High-impact AMPAR PAM decreases both deactivation and desensitization together to enhance and prolong synaptic currents.
|
||
|
INHIBITOR -> TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents.
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
ACTIVATOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
This action is very weak and its clinical effects may not necessarily be mediated by this action.
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
NEGATIVE ALLOSTERIC MODULATOR (NAM)->TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents.
|
||
|
INHIBITOR -> TARGET |
Endogenous ligand
|
||
|
INHIBITOR -> TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
High-impact AMPAR PAM decreases both deactivation and desensitization together to enhance and prolong synaptic currents.
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
|
||
|
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents.
ALLOSTERIC ACTIVATOR
|
||
|
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET |
|
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO ACID SUBSTITUTION | [1_836] [1_839] [1_856] | DEXFOSFOSERINE | VI4F0K069V |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT | CHEMICAL |
|